# HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma

> **NCT05290116** · PHASE2 · UNKNOWN · sponsor: **Yunfei Yuan** · enrollment: 17 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **DRUG:** HAIC Combined with Tislelizumab and Apatinib

## Key facts

- **NCT ID:** NCT05290116
- **Lead sponsor:** Yunfei Yuan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-21
- **Primary completion:** 2023-05-01
- **Final completion:** 2023-09-01
- **Target enrollment:** 17 (ESTIMATED)
- **Last updated:** 2022-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05290116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05290116, "HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05290116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*